- Prostaglandin D2 production in obese mice is associated with reduced lung inflammation and improved control of Francisella tularensis and Bordetella pertussis infectionby inmunoadminJ Immunol. 2026 Aug 29;215(9):vkag254. doi: 10.1093/jimmun/vkag254. ABSTRACT Obesity is a risk factor for severe respiratory viral infections, but its impact on bacterial respiratory diseases remains unclear and is sometimes paradoxical. Herein, we demonstrate that diet-induced obese, male C57BL/6J mice exhibited increased resistance to pulmonary infection with Francisella tularensis and Bordetella pertussis compared with lean … Read more
- Dissecting the mechanism of action of the adjuvant system AS01 in human immune cells: synergy of QS-21 and monophosphoryl lipid A and role of type I interferonsby Michelle PoeThe adjuvant system AS01 comprised of the TLR4 agonist monophosphoryl lipid A (MPLA) and the saponin QS-21 embedded in liposomes is currently used in recombinant vaccines against shingles, respiratory syncytial virus infection, and malaria. The efficac…
- Maternal rubella immunity gaps in the vaccine era: a seroepidemiological study of pregnant women in Jiangsu, Chinaby Xiang SunBackgroundRubella elimination has substantially reduced virus circulation in China, but the changing pattern of immunity among women entering reproductive age remains unclear. We assessed the contemporary rubella immunity profile among pregnant women i…
- Transient short-chain fatty acid exposure and the temporal question of epithelial barrier immunityby Rebecca LewandowskiStudies of microbiome-targeted interventions often use persistence of an administered organism or endpoint metabolite abundance as markers of biological consequence, but host barriers may be altered by microbial chemistry after the initiating exposure …
- Real-world outcomes of atezolizumab–bevacizumab and durvalumab–tremelimumab in unresectable hepatocellular carcinoma: a systematic review with covariate-adjusted meta-regression and exploratory machine learning analysisby Jongin LeeBackground/purposeAtezolizumab–bevacizumab (AB) and durvalumab–tremelimumab (DT) are standard first-line therapies for unresectable hepatocellular carcinoma (uHCC), but their comparative effectiveness remains uncertain.MethodsWe included 76 observation…